Drug Trial Radar · NCT01431274
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Jul 16, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,624
Actual
Start
Sep 2011
Primary completion
Sep 2013
Study completion Sep 2013
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 9, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterolDrug
fixed dose combination
tiotropiumDrug
low dose
olodaterolDrug
one dose only
tiotropiumDrug
high dose
tiotropium + olodaterolDrug
fixed dose combination
RespimatDevice
Respimat inhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169.Time frame: 1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169.
- Trough FEV1 Response on Day 170.Time frame: 1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170
- Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)Time frame: Day 169
Locations
239 sites in 25 countries. Site status is shown where the registry gives one.
1237.5.01038 Boehringer Ingelheim Investigational Site
Jasper, Alabama
1237.5.01036 Boehringer Ingelheim Investigational Site
Mobile, Alabama
1237.5.01015 Boehringer Ingelheim Investigational Site
Boulder, Colorado
1237.5.01024 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado
1237.5.01034 Boehringer Ingelheim Investigational Site
Stamford, Connecticut
1237.5.01003 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1237.5.01010 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1237.5.01027 Boehringer Ingelheim Investigational Site
Panama City, Florida
1237.5.01031 Boehringer Ingelheim Investigational Site
O'Fallon, Illinois
1237.5.01035 Boehringer Ingelheim Investigational Site
Opelousas, Louisiana
1237.5.01004 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana
1237.5.01017 Boehringer Ingelheim Investigational Site
Biddeford, Maine
1237.5.01028 Boehringer Ingelheim Investigational Site
Columbia, Maryland
1237.5.01013 Boehringer Ingelheim Investigational Site
Livonia, Michigan
1237.5.01019 Boehringer Ingelheim Investigational Site
Omaha, Nebraska
1237.5.01025 Boehringer Ingelheim Investigational Site
Larchmont, New York
1237.5.01008 Boehringer Ingelheim Investigational Site
Rochester, New York
1237.5.01023 Boehringer Ingelheim Investigational Site
Raleigh, North Carolina
1237.5.01016 Boehringer Ingelheim Investigational Site
Tabor City, North Carolina
1237.5.01006 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
1237.5.01040 Boehringer Ingelheim Investigational Site
Columbus, Ohio
1237.5.01039 Boehringer Ingelheim Investigational Site
Dayton, Ohio
1237.5.01037 Boehringer Ingelheim Investigational Site
Toledo, Ohio
1237.5.01009 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma
1237.5.01032 Boehringer Ingelheim Investigational Site
Charleston, Pennsylvania
1237.5.01005 Boehringer Ingelheim Investigational Site
Johnston, Rhode Island
1237.5.01021 Boehringer Ingelheim Investigational Site
Easley, South Carolina
1237.5.01012 Boehringer Ingelheim Investigational Site
Gaffney, South Carolina
1237.5.01014 Boehringer Ingelheim Investigational Site
Spartanburg, South Carolina
1237.5.01029 Boehringer Ingelheim Investigational Site
Fort Worth, Texas
1237.5.01002 Boehringer Ingelheim Investigational Site
San Antonio, Texas
1237.5.01026 Boehringer Ingelheim Investigational Site
Lynchburg, Virginia
1237.5.01007 Boehringer Ingelheim Investigational Site
Spokane, Washington
1237.5.01033 Boehringer Ingelheim Investigational Site
Tacoma, Washington
1237.5.01001 Boehringer Ingelheim Investigational Site
Morgantown, West Virginia
1237.5.54010 Boehringer Ingelheim Investigational Site
Buenos Aires, Argentina
1237.5.54013 Boehringer Ingelheim Investigational Site
Caba, Argentina
1237.5.54016 Boehringer Ingelheim Investigational Site
Caba, Argentina
1237.5.54003 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1237.5.54002 Boehringer Ingelheim Investigational Site
Cuidad Autonoma de Buenos Airess A, Argentina
Showing 40 of 239 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.